Results from the randomized, double blind and placebo-controlled Phase II trial show significant improvements in hyperphagia-related behavior, a key therapeutic objective in Prader-Willi Syndrome.
from Obesity / Weight Loss / Fitness News From Medical News Today http://ift.tt/1T4nzQf
mercredi 27 avril 2016
weight loss fitnessAlizé Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome
Inscription à :
Publier les commentaires (Atom)
0 commentaires:
Enregistrer un commentaire